RE:RE:RE:RE:Taking it in the ChinThis is their North American Portfolio which is 34% of earnings. Zonegran was doing fine. Dyrenium is peanuts. Real concern is Plaquenil which they are doign fine on - and pricing pressure is already baked in + impairment is already realized.
| North American Port | | |
| Covis | | Original | |
| Plaquenil | 30.50% | Donnatal | 21.60% |
| Nilandron | 7.70% | Zonegran | 12.20% |
| Other | 8% | Other | 7% |
| Lanoxin | 13.20% | Total | 40.60% |
| Total | 59% | | |